Kudarat, Uting Y.
HRN: 14-80-62 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/04/2024
CO-AMOXICLAV 625MG (TAB)
03/04/2024
03/11/2024
PO
625
BiD
DM FOOT
Waiting Final Action
Indication: Prophylaxis Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes